DNL

Diurnal GroupAIM:DNL Stock Report

Market Cap

UK£94.6m

7D

2.8%

1Y

-22.7%

Updated

22 Sep, 2021

Data

Company Financials +
DNL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

DNL Overview

Diurnal Group plc operates as a specialty pharma company worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for Diurnal Group
Historical stock prices
Current Share PriceUK£0.56
52 Week HighUK£0.47
52 Week LowUK£0.98
Beta1.24
1 Month Change-6.98%
3 Month Change-11.11%
1 Year Change-22.65%
3 Year Change-49.55%
5 Year Change-60.70%
Change since IPO-63.40%

Recent News & Updates

Shareholder Returns

DNLGB BiotechsGB Market
7D2.8%2.4%0.6%
1Y-22.7%36.6%23.1%

Return vs Industry: DNL underperformed the UK Biotechs industry which returned 36% over the past year.

Return vs Market: DNL underperformed the UK Market which returned 22.6% over the past year.

Price Volatility

Is DNL's price volatile compared to industry and market?
DNL volatility
DNL Beta1.24
Industry Beta0.83
Market Beta1

Stable Share Price: DNL is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: DNL's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201529Martin Whitakerhttps://www.diurnal.co.uk

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe.

Diurnal Group Fundamentals Summary

How do Diurnal Group's earnings and revenue compare to its market cap?
DNL fundamental statistics
Market CapUK£94.59m
Earnings (TTM)-UK£10.05m
Revenue (TTM)UK£4.37m

21.6x

P/S Ratio

-9.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DNL income statement (TTM)
RevenueUK£4.37m
Cost of RevenueUK£779.00k
Gross ProfitUK£3.59m
ExpensesUK£13.64m
Earnings-UK£10.05m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.073
Gross Margin82.18%
Net Profit Margin-229.90%
Debt/Equity Ratio0.0%

How did DNL perform over the long term?

See historical performance and comparison

Valuation

Is Diurnal Group undervalued compared to its fair value and its price relative to the market?

2.52x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DNL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DNL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DNL is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: DNL is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DNL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DNL is good value based on its PB Ratio (2.5x) compared to the GB Biotechs industry average (6.3x).


Future Growth

How is Diurnal Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

60.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DNL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).

Earnings vs Market: DNL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DNL's is expected to become profitable in the next 3 years.

Revenue vs Market: DNL's revenue (48.6% per year) is forecast to grow faster than the UK market (5.5% per year).

High Growth Revenue: DNL's revenue (48.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DNL's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Diurnal Group performed over the past 5 years?

5.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DNL is currently unprofitable.

Growing Profit Margin: DNL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DNL is unprofitable, but has reduced losses over the past 5 years at a rate of 5.7% per year.

Accelerating Growth: Unable to compare DNL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DNL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (19.9%).


Return on Equity

High ROE: DNL has a negative Return on Equity (-26.75%), as it is currently unprofitable.


Financial Health

How is Diurnal Group's financial position?


Financial Position Analysis

Short Term Liabilities: DNL's short term assets (£41.6M) exceed its short term liabilities (£4.2M).

Long Term Liabilities: DNL's short term assets (£41.6M) exceed its long term liabilities (£63.0K).


Debt to Equity History and Analysis

Debt Level: DNL is debt free.

Reducing Debt: DNL has no debt compared to 5 years ago when its debt to equity ratio was 12.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DNL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DNL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 6% each year


Dividend

What is Diurnal Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DNL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DNL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DNL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DNL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DNL's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average board tenure


CEO

Martin Whitaker

no data

Tenure

UK£512,000

Compensation

Dr. Martin Whitaker, BSc, Ph D., serves as the Chief Executive Officer and Executive Director of Diurnal Group Plc since December 1, 2015. Dr. Whitaker serves as an Operations Director of Critical Pharmace...


CEO Compensation Analysis

Compensation vs Market: Martin's total compensation ($USD699.39K) is above average for companies of similar size in the UK market ($USD326.10K).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: DNL's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DNL insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.4%.


Top Shareholders

Company Information

Diurnal Group plc's employee growth, exchange listings and data sources


Key Information

  • Name: Diurnal Group plc
  • Ticker: DNL
  • Exchange: AIM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£94.586m
  • Shares outstanding: 168.90m
  • Website: https://www.diurnal.co.uk

Number of Employees


Location

  • Diurnal Group plc
  • Cardiff MediCentre
  • Heath Park
  • Cardiff
  • South Glamorgan
  • CF14 4UJ
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 21:19
End of Day Share Price2021/09/22 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.